MA-RENAGADE-THERAPEUTICS
27.2.2024 14:01:39 CET | Business Wire | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
“Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade. “In this newly created position, Joe will advise the company on research strategy and direction as well as help drive our lead programs towards development milestones. We are very excited to welcome him to the team.”
“ReNAgade is leading the industry in its efforts to transcend the boundaries of RNA medicine,” said Dr. Bolen. “I am thrilled to join the company and undertake an important role in shaping research plans as we work together to translate ReNAgade’s multi-modal RNA platform into therapeutic advances for patients with high unmet medical needs.”
Dr. Bolen brings more than 45 years of industry and research experience to ReNAgade. He is an Executive Partner at MPM BioImpact and was formerly Chief Scientific Officer at PureTech Health. Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer. Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company. Prior to joining Millennium in 1999, Dr. Bolen held senior R&D positions at Hoechst Marion Roussel, Schering-Plough (DNAX) and Bristol Myers Squibb. He began his career at the National Institutes of Health (NIH), where he contributed to the discovery of a class of proteins known as tyrosine kinase oncogenes as key regulators of the immune system. Joe earned a Ph.D. in Immunology and conducted his postdoctoral training in molecular virology at Kansas State University Cancer Center. He graduated from the University of Nebraska with a B.S. in Microbiology and Chemistry.
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit https://renagadetx.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227482038/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ITC Infotech Strengthens Strategic Tech Partnership With British American Tobacco (BAT) in New Multi-year Mandate12.8.2026 12:30:00 CEST | Press release
ITC Infotech, a leading global technology services and solutions provider, today announced a landmark multi‑year strategic technology deal with British American Tobacco (BAT). Along with BAT, ITC Infotech will accelerate the transformation of BAT’s technology landscape to drive AI-enabled innovation, strengthen skills, and improve efficiencies. In this expanded partnership, ITC Infotech will provide technology services to BAT across Poland, Romania and India. ITC Infotech will also continue to collaborate with BAT to scale capabilities at the newly launched BAT Future Capabilities Centre in India, while supporting BAT’s existing technology hubs in Malaysia and Mexico. This new strategic deal will deepen an already well-established partnership between ITC Infotech and BAT, streamlining end-to-end technology delivery and improving speed, efficiency, and service quality. As part of the deal, ITC Infotech will strengthen its footprint and onshore capabilities in Europe, which will be strat
Gen Z Spending is Expected to Reach $12 Trillion by 2030. Here's Why That Doesn't Matter as Much as Brands Think12.8.2026 12:00:00 CEST | Press release
New NIQ report reveals consumers across generations are trading up and trading down in the same shopping basket, putting new pressure on middle-market products The biggest shift in consumer spending isn't generational—it's behavioral. New research from NielsenIQ (NYSE: NIQ) finds consumers across every age group are increasingly making the same calculation: where is a premium worth paying, and where can they save money instead? The result is a growing divide between premium and value products, while traditional middle-market offerings face mounting pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812239453/en/ Every generation is spending differently, but all are weighing value more carefully The findings come from NIQ's latest global report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, developed in collaboration with World Data Lab. While Gen X accounted for $15.2 trillion in sp
Kinguin Renews Ravelin Partnership After Cutting Ecommerce Fraud to “Industry-Leading Low”12.8.2026 11:04:00 CEST | Press release
Leading games marketplace extends AI fraud prevention deal for further three years Ravelin automates real-time fraud defenses and supports growth to over 20 million customers Kinguin, a global digital games marketplace serving more than 20 million registered users, has renewed its partnership with AI-native fraud platform Ravelin. The agreement follows significant reductions in fraud and a shift to automated, scalable fraud detection. Since first partnering in 2018, Ravelin has helped Kinguin transform its approach to payment fraud. Kinguin has eliminated the need for real-time manual reviews, while overall fraud rates have declined by 87.5%. The renewal reflects growing confidence in AI-led fraud prevention at a time when ecommerce merchants face increasingly sophisticated attacks, particularly in the digital goods space where instant delivery also means instant results for fraudsters. Kinguin is where gaming and esports fans around the world can access their favorite games, choosing
Delhaize BeLux Achieves Up to 90% Forecast Accuracy Using SymphonyAI's AI-Driven Replenishment Platform12.8.2026 09:05:00 CEST | Press release
Ahold Delhaize grocery retailer deploys SymphonyAI across 600 stores and five distribution centers, cutting shrink and improving forecast accuracy by up to 10 percentage points When a grocery retailer operates under a pure B2B affiliate model, it cannot push excess inventory to its store partners — which means forecasting has to be right, or the distribution center absorbs the cost. SymphonyAI, a global leader in Vertical AI, today announced that Delhaize, part of the Ahold Delhaize Group, has deployed SymphonyAI's Demand Forecasting and Replenishment solutions across its 600-store affiliated network and five distribution centers in Belgium, replacing reactive, manually intensive ordering processes with an AI-driven, exception-based workflow. The Delhaize Le Lion / De Leeuw network has no less than 1113 stores in Belgium and Luxembourg. The store network consists of different formulas: Delhaize, Proxy, Shop&Go and louis delhaize. Customers can also shop online via www.delhaize.be, and
Align Technology Prevails in China Patent Infringement Action Against Angelalign12.8.2026 02:47:00 CEST | Press release
Align Technology, Inc. ("Align") (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, today announced that the Jinan Intermediate People's Court in China issued a judgment in favor of Align in a patent infringement action against Angelalign Technology's operating subsidiaries in China ("Angel") (Hong Kong Stock Exchange: 6699.HK). In September 2025, Align filed a patent infringement action against Angel in the Jinan Intermediate People's Court, asserting Align’s patent related to extraction-gap-closure technology (CN113693748B). On August 10, 2026, the Jinan Intermediate People's Court issued a first-instance judgment finding that Angel's use of its MasterForce biomechanical simulation system and ATreat digital orthodontic treatment design system to generate A7 and A7 Speed premolar extraction treatment solutions infringes Align's patent rights. The court further found that the related aligner products m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom